CIRCULOGENE’s Molecular Genetics Testing Ventures Into International Licensing Agreement With Turkey-Based Circulogene Saglik

Advanced precision medicine CIRCULOGENE through its molecular genetics testing enters into an international licensing agreement with turkey based CIRCULOGENE Saglik.

As per the terms of the agreement , CIRCULOGENE’s low-volume, high-yield extraction – free sample generation together with next generation sequencing technology is being licensed to CIRCULOGENE Saglik of Istanbul, Turkey.

Gökşin Özel, Co- Founder, Chairman and CEO of CIRCULOGENE Saglik expresses joy over the licensing agreement asserting “We strongly believe in CIRCULOGENE’s technology and in the importance of partnering with health care professionals to help save and extend lives. We are also committed to serving the communities in which we live and work, and providing the highest level of customer service possible.”

The agreement permits exclusive rights to use CIRCULOGENE’S propriety, direct-on specimen, nucleic-acid enrichment technology in Turkey and surrounding regions like parts of Europe, Africa, the Middle East and Commonwealth of Independent States. In March, 2016, CIRCULOGENE commenced processing its international orders from GGT Global Genetik, parent company of CIRCULOGENE Saglik. CIRCULOGENE has just introduced Microsatellite instability biomarker testing for succint cancer immunotherapy with keytruda across varied cancer types or Opdivo for colorectal cancer. The company’s laboratory operations have been automated and advanced ensuring world-class amenities for an industry- leading and enriching experience incorporating all DNA, RNA and immunotherapy yest results at cost- effective prices.

CIRCULOGENE is Clinical Laboratory Improvement Amendments (CLIA) certified that allows physicians to test and compare results to certain drugs and clinical trials.